Cantor Fitzgerald analyst Kirsten Kluska reiterated an Overweight rating and $109.00 price target on Monopar Therapeutics (NASDAQ: MNPR)The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE